Periodontitis - Pipeline Review, H1 2018

  • ID: 4473124
  • Drug Pipelines
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Cells for Cells SA
  • CSL Ltd
  • Geistlich Pharma AG
  • MORE
Periodontitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Pipeline Review, H1 2018, provides an overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape.

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Periodontitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Periodontitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Periodontitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Periodontitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
  • The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)
Reasons to Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Cells for Cells SA
  • CSL Ltd
  • Geistlich Pharma AG
  • MORE
Introduction

Report Coverage

Periodontitis - Overview

Periodontitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Periodontitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Periodontitis - Companies Involved in Therapeutics Development

Cells for Cells SA

CSL Ltd

Geistlich Pharma AG

Kuhnil Pharmaceutical Co Ltd

Periodontitis - Drug Profiles

AMY-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Antagonize C5aR for Periodontitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myc-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PODCRC-OHS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-10001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ranokure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Periodontitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taurolidine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Periodontitis - Dormant Projects

Periodontitis - Discontinued Products

Periodontitis - Product Development Milestones

Featured News & Press Releases

Dec 13, 2017: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-

Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis

Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis

May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Periodontitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Periodontitis - Pipeline by Cells for Cells SA, H1 2018

Periodontitis - Pipeline by CSL Ltd, H1 2018

Periodontitis - Pipeline by Geistlich Pharma AG, H1 2018

Periodontitis - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2018

Periodontitis - Dormant Projects, H1 2018

Periodontitis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Periodontitis - Discontinued Products, H1 2018

List of Figures:

Number of Products under Development for Periodontitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cells for Cells SA
  • CSL Ltd
  • Geistlich Pharma AG
  • Kuhnil Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll